Ratings by RBC Capital (Brian Abraham)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/10/2026 | BioCryst Pharma | BCRX | Downgrade | Sector Perform (Outperform) |
8.81 (7.79) |
-11.58% | Details | |
| 8/6/2026 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | BioCryst Pharma | BCRX | Maintain | (N/A) |
|
Details | ||
| 3/25/2026 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2026 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2025 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2025 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2025 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2025 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2025 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/18/2023 | BioCryst Pharma | BCRX | Upgrade | Outperform (Sector Perform) |
6.85 (8.81) |
28.61% | Details | |
| 8/4/2023 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/2/2022 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 8/5/2022 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/6/2022 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 4/12/2022 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/4/2021 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 8/6/2021 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/7/2021 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 8/7/2020 | BioCryst Pharma | BCRX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/24/2019 | BioCryst Pharma | BCRX | Downgrade | Sector Perform (Outperform) |
3.54 (7.79) |
120.06% | Details | |
| 12/4/2018 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/4/2018 | BioCryst Pharma | BCRX | Maintain | Outperform (N/A) |
|
Details |
